Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study - Report - MDSpire
Advertisement
Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study
This report discusses the development of a benchmark for evaluating reimbursement eligibility of anticancer medications in South Korea using large language models (LLMs). The benchmark aims to assess LLM reliability in determining eligibility under conditions of incomplete clinical evidence.
Background
Billing and insurance-related activities significantly contribute to healthcare costs in the U.S., with a notable impact on both patients and clinicians. In South Korea, the National Health Insurance system requires complex eligibility assessments for anticancer drugs, which have become increasingly intricate due to rising costs and evolving clinical criteria. This complexity necessitates reliable methods for evaluating reimbursement eligibility.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
The benchmark developed assesses eligibility for anticancer drugs based on South Korea's national guidelines.
It includes cases that are eligible, ineligible, and undeterminable to evaluate correctness and recognition of insufficient evidence.
LLMs have shown potential in supporting reimbursement-related tasks but require structured logical reasoning for eligibility determinations.
Errors in LLM outputs can lead to critical mistakes in medical domains, particularly in complex decision-making scenarios.
Manual review of eligibility criteria is prone to errors due to the intricate nature of the rules involved.
Clinical Implications
The benchmark provides a structured approach to evaluate LLMs in the context of reimbursement eligibility, which may help reduce administrative burdens in clinical practice. Understanding the limitations of LLMs in this domain is crucial for ensuring accurate reimbursement decisions.
Conclusion
The development of this benchmark represents a significant step towards improving the reliability of LLMs in determining anticancer medication reimbursement eligibility under real-world constraints.
